Preclinical efficacy and safety of Tegavivint in Wnt-activated hepatocellular carcinoma
Toshiyasu Suzuki, Ciara Curran, Thomas M Drake, Stephanie May, Kyi Lai Yin Swe, Αναστασία Γεωργακοπούλου, Megan Quince, Fiona E. Chalmers, Emma Paterson, Aundrietta D. Duncan, Stephen K. Horrigan, Mark E. Kelly, Colin Nixon, Victor Hugo Villar, Thomas Graham Bird
This study evaluates Tegavivint's efficacy and safety in Wnt-activated HCC, showing potent anti-tumour activity and safety in preclinical models.
bioRxiv · Jul 16, 2026 · PreprintCancer Biology